Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Farmington Hills, MI
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
St. Charles, MO
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
St. Charles, MO
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Clementon, NJ
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Clementon, NJ
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Brooklyn, NY
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
New York, NY
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Beachwood, OH
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Beachwood, OH
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Eugene, OR
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Portland, OR
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Memphis, TN
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Austin, TX
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Irving, TX
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Irving, TX
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Lake Jackson, TX
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Lake Jackson, TX
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Bellevue, WA
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Bellevue, WA
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Edmonton,
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Edmonton,
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Peoria, AZ
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Peoria, AZ
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Scottsdale, AZ
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Garden Grove, CA
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Irvine, CA
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Irvine, CA
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
National City, CA
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
National City, CA
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Miami, FL
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Winter Park, FL
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Winter Park, FL
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Springfield, IL
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Terre Haute, IN
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Terre Haute, IN
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Florence, KY
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Florence, KY
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Brockton, MA
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Brockton, MA
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
New York, NY
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Chapel Hill, NC
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Raleigh, NC
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Lyndhurst, OH
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Lyndhurst, OH
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Eugene, OR
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Philadelphia, PA
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Austin, TX
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Galveston, TX
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Galveston, TX
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Lake Jackson, TX
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Lake Jackson, TX
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Salt Lake City, UT
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
Multimodal Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
Status: Enrolling
Updated:  5/1/2015
McLean Hospital
mi
from
Belmont, MA
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
Multimodal Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
Status: Enrolling
Updated: 5/1/2015
McLean Hospital
mi
from
Belmont, MA
Click here to add this to my saved trials
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
Multimodal Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
Status: Enrolling
Updated:  5/1/2015
McLean Imaging Center/McLean TMS Service
mi
from
Belmont, MA
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
Multimodal Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
Status: Enrolling
Updated: 5/1/2015
McLean Imaging Center/McLean TMS Service
mi
from
Belmont, MA
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site #023
mi
from
Beverly Hills, CA
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site #023
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site 007
mi
from
San Diego, CA
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site 007
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site 005
mi
from
Riverside, CA
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site 005
mi
from
Riverside, CA
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site 29
mi
from
Hartford, CT
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site 29
mi
from
Hartford, CT
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site 006
mi
from
Ft. Lauderdale, FL
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site 006
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site 15
mi
from
Leesburg, FL
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site 15
mi
from
Leesburg, FL
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site 011
mi
from
Hoffman Estates, IL
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site 011
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site #010
mi
from
Boston, MA
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site #010
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site 13
mi
from
Weymouth, MA
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site 13
mi
from
Weymouth, MA
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site 28
mi
from
Rochester Hills, MI
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site 28
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site 051
mi
from
Brooklyn, NY
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site 051
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site
mi
from
Memphis, TN
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  5/15/2015
Forest Investigative Site
mi
from
Houston, TX
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 5/15/2015
Forest Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials